2026年8月12日 / 美国东部时间早上6:06 / 哥伦比亚广播公司新闻
礼来公司周三表示，已起诉六家销售其试验性减肥药瑞特鲁肽（retatrutide）仿制品的公司，并称这是打击庞大非法市场的专项行动的开端。
尽管瑞特鲁肽仍处于临床试验阶段，尚未获得美国食品药品监督管理局批准为安全有效的药物，但该非法市场已蓬勃发展。联邦法律禁止未经批准的药物进行商业销售，但由于礼来公司试验的积极结果在社交媒体上引发了对该药物的狂热追捧，许多远程医疗公司、诊所和在线肽类供应商仍决定提供这款新一代药物。
“这是一个全球性问题，而且规模巨大，”礼来公司副总裁马克斯·丹宁在接受采访时表示，他呼吁监管机构、社交媒体公司、支付处理商等各方共同协助遏制瑞特鲁肽的非法销售。“六起诉讼并非能解决所有问题，但这是一个开端，”他说道。
礼来公司宣布的诉讼针对多家营销瑞特鲁肽的公司，丹宁表示这些药物由“海外制造商”供应。被这家制药公司起诉的四家公司均在无处方的情况下，以“仅供研究使用”为由宣传该产品：阿斯特拉肽业、传奇肽业、德克萨斯肽业和孤星肽业。礼来公司还起诉了加利福尼亚州一家名为“Aesthetic Envy”的医美诊所，该诊所宣传销售瑞特鲁肽，以及Striker药房，该药房仿制了这款试验性药物。Striker药房是哥伦比亚广播公司新闻6月调查中确认的数家仿制瑞特鲁肽的复合药房之一。
截至周三早间，这些公司均未立即回应置评请求。
礼来公司正在开展晚期临床试验，将瑞特鲁肽作为肥胖症和2型糖尿病的治疗手段进行研究，目前的结果显示，其疗效可能优于美国食品药品监督管理局已批准的最强效减肥药。该制药公司上月表示，计划于2027年初为该药物申请监管批准。
华尔街分析师预计瑞特鲁肽将成为重磅炸弹级药物，但也对非法市场表示担忧。上周，一名金融分析师问及该公司是否有“针对当前市面上各类非法产品的保护策略”时，礼来公司一名高管对此不予置评。
根据标普全球市场情报汇编的会议记录，执行副总裁肯尼思·卡斯特表示：“我认为人们都在热切期待正宗的瑞特鲁肽能上市销售。”
尽管礼来公司希望监管机构和执法部门能对声称销售瑞特鲁肽的公司采取更多行动，但此类公开销售的行为日益增多，且似乎几乎没有受到任何处罚。
哥伦比亚广播公司新闻上月报道称，便利店正在广告宣传并销售研究级瑞特鲁肽小瓶。截至8月8日，布鲁克林的两家熟食店仍在张贴广告，宣传该药物及其他肽类产品。其中一家名为“格林先生”的店铺的收银员表示，瑞特鲁肽已售罄。
杰米·科恩布拉特为本报道撰稿。
Eli Lilly takes aim at illicit market for its experimental weight-loss drug
August 12, 2026 / 6:06 AM EDT / CBS News
Eli Lilly said Wednesday it is suing six companies selling versions of its experimental weight-loss drug retatrutide, calling it the beginning of a concerted effort to crack down on a vast illicit market.
That market has boomed even though retatrutide is still being studied in clinical trials and hasn’t been approved by the Food and Drug Administration as safe and effective. Federal law prohibits the commercial sale of unapproved drugs, but many telehealth firms, clinics and peptide vendors online have decided to offer the next-generation drug anyway, as promising results from Eli Lilly’s trials have fueled a craze for it on social media.
“This is a global problem and it’s an enormous one,” Max Denning, an associate vice president at Eli Lilly, said in an interview, calling on regulators, social media companies, payment processors and others to help stem illicit sales of retatrutide. “Six lawsuits is not going to be the solution to everything, but it is a start,” he said.
The lawsuits Eli Lilly announced target a variety of companies that market retatrutide, which Denning said is being supplied by “overseas manufacturers.” Four of the firms targeted by the drugmaker advertise the product “for research use” without a prescription: Astra Peptides, Legendary Peptides, Texas Peptides and Lone Star Peptide. Eli Lilly is also suing Aesthetic Envy, a California med spa that promotes retatrutide, and Striker Pharmacy, which has made a version of the experimental drug. Striker is one of several compounding pharmacies that have made imitation retatrutide identified by CBS News in a June investigation.
The companies didn’t immediately respond to requests for comment early Wednesday.
Eli Lilly is running late-stage clinical trials to study retatrutide as a treatment for obesity and type 2 diabetes, and results so far have shown that it could be more effective than the most potent weight-loss drugs that have been approved by the FDA. The drugmaker said last month that it plans to seek regulatory approval for the drug in early 2027.
Wall Street analysts expect retatrutide to be a blockbuster, but have voiced concern about the illicit market. Asked last week by a financial analyst if the company had a strategy “to protect against whatever it is that’s apparently available today,” an Eli Lilly executive shrugged it off.
“I think people are eagerly awaiting authentic retatrutide to be available in the market,” said Kenneth Custer, an executive vice president, according to a transcript compiled by S&P Global Market Intelligence.
While Eli Lilly is hoping that regulators and law enforcement will take more action against companies claiming to sell retatrutide, some are increasingly doing so in the open, with apparently few if any consequences.
CBS News reported last month that convenience stores were advertising and selling vials of research-grade retatrutide. As recently as Aug. 8, two bodegas in Brooklyn still displayed posters advertising it along with other peptides. A cashier at one of them, a store called Mr. Green, said they were sold out of retatrutide.
Jamie Korenblat contributed to this report.
发表回复